Press Releases
Press Releases
-
Rezolute Management to Present at 2019 BIO Investor Forum Conference
-
Rezolute Management to Present at 2019 Canaccord Genuity Growth Conference
-
Rezolute Completes $45 Million Investment Round with Full Exercise of $20 Million Option
-
Rezolute Announces $25 Million Private Placement -- Potential Total Investment of $45 Million
-
Rezolute Announces Appointment of Keith Vendola as Chief Financial Officer
-
Rezolute Announces Appointment of Congenital Hyperinsulinism Therapeutic Area Expert, Dr. Christine Ferrara, as Director of Clinical Development
-
Rezolute Announces Appointment of Hoyoung Huh, M.D., Ph.D. as Vice Chairman of its Board of Directors
-
Rezolute, Inc. Announces Close of Convertible Note Financing
-
UPDATE - Rezolute, Inc. Enters into Common Stock Purchase Agreement for Up to $10 Million with Lincoln Park Capital Fund, LLC
-
AntriaBio Announces Exclusive License Agreement for a Phase 2 Orphan Disease Therapy with XOMA Corporation and Name Change to Rezolute, Inc.
